Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of just 7%. Its late diagnosis and limited treatment options contribute to poor outcomes. Immunotherapy has had little success due to PDAC’s dense and immunosuppressive tumor environment. Emerging mRNA v...

Full description

Saved in:
Bibliographic Details
Main Authors: Aariz Hussain, Areeba Fareed
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Journal of Genetic Engineering and Biotechnology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1687157X25000137
Tags: Add Tag
No Tags, Be the first to tag this record!